Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...
Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...
Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.
Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...
Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, according to new research recently published in Cancer Immunology Research.
Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...
Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the ...
A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...
The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival rate for all cancers combined has reached 70%, up from 49% in the mid-1970s.
Baar, Switzerland Wednesday, March 4, 2026, 17:00 Hrs [IST] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results